{
  "report_rows": [
    {
      "kpi": "Core revenue growth",
      "prediction": "BEAT",
      "answer": "pred ~2.4% vs. cons 2.0%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.89 vs. cons $1.84",
      "confidence": "HIGH"
    },
    {
      "kpi": "Adjusted operating margin",
      "prediction": "BEAT",
      "answer": "pred ~27.0% vs. cons 26.6%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted diluted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$8.48 midpoint ($8.40-$8.55) vs. cons $8.47 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Core revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~3%-6% vs. cons 3.4% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Core revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~4.0% vs. cons 4.0% (2026Q3)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted operating margin guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~26.0% vs. cons 26.1% (2026Q3)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.1,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.2,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Modest FY2026 EPS revisions and de-risked second-half core-growth math should extend the initial reaction; sustained bioprocessing equipment orders and improving Life Sciences bookings would lift 2027 estimates rather than reveal an implicit out-period cut.",
  "day5_confidence": "MEDIUM"
}